Business Description
Flerie AB
ISIN : SE0022447348
Total Employee Number:
6Compare
Compare
Traded in other countries / regions
FLERIE.Sweden1NP1.Germany IPO Date
2016-10-11Description
Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations. It operates in two segments The Product Development segment, and The Commercial Growth segment. The Product Development segment consists of early and mid-stage biotech and pharma companies advancing their products and technologies toward clinical proofof-concept and marketing approvals. The Commercial Growth segment consists of companies already selling products or services, showcasing their ability to generate increasing revenues ahead of reaching sustainable profitability.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 179.82 | |||||
Equity-to-Asset | 1 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 66.75 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 16.8 | |||||
3-Year FCF Growth Rate | 74.6 | |||||
3-Year Book Growth Rate | -11.4 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 54.87 | |||||
9-Day RSI | 50.85 | |||||
14-Day RSI | 48.36 | |||||
3-1 Month Momentum % | -14.29 | |||||
6-1 Month Momentum % | -34.33 | |||||
12-1 Month Momentum % | -46.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 66.45 | |||||
Quick Ratio | 66.45 | |||||
Cash Ratio | 36.39 | |||||
Days Sales Outstanding | 142.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -144.1 | |||||
Shareholder Yield % | 5.92 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -2173.68 | |||||
Net Margin % | -43863.16 | |||||
EBITDA Margin % | -38442.11 | |||||
FCF Margin % | -1968.42 | |||||
OCF Margin % | -1968.42 | |||||
ROE % | -22.55 | |||||
ROA % | -22.46 | |||||
ROIC % | -1.3 | |||||
3-Year ROIIC % | 4.16 | |||||
ROC (Joel Greenblatt) % | -59918.03 | |||||
ROCE % | -19.75 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 976.2 | |||||
PB Ratio | 0.52 | |||||
Price-to-Tangible-Book | 0.52 | |||||
EV-to-EBIT | -2.02 | |||||
EV-to-EBITDA | -2.02 | |||||
EV-to-Revenue | 775.42 | |||||
EV-to-FCF | -40.09 | |||||
Price-to-Projected-FCF | 0.84 | |||||
| Price-to-Net-Current-Asset-Value | 3.27 | |||||
| Price-to-Net-Cash | 6.14 | |||||
Earnings Yield (Greenblatt) % | -49.64 | |||||
FCF Yield % | -2.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Flerie AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 1.9 | ||
| EPS (TTM) (kr) | -9.369 | ||
| Beta | -0.7719 | ||
| 3-Year Sharpe Ratio | -0.1 | ||
| 3-Year Sortino Ratio | -0.14 | ||
| Volatility % | 26.76 | ||
| 14-Day RSI | 48.36 | ||
| 14-Day ATR (kr) | 0.652042 | ||
| 20-Day SMA (kr) | 20.535 | ||
| 12-1 Month Momentum % | -46.03 | ||
| 52-Week Range (kr) | 19.4 - 39.856249 | ||
| Shares Outstanding (Mil) | 86.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Flerie AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Flerie AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-01-20 | In 169 days | ||
| Fourth quarter earnings results for 2026 | 2027-01-20 | In 169 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-15 | In 72 days | ||
| Third quarter earnings results for 2026 | 2026-10-15 | In 72 days | ||
| Second quarter earnings results for 2026 | 2026-07-09 | 21.10 (+0.48%) | ||
| 1.14286:1 Stock Split | 2026-05-15 | 24.67 (+3.30%) | ||
| First quarter earnings conference call for 2026 | 2026-04-15 11:00 | 25.11 (-0.35%) | ||
| First quarter earnings results for 2026 | 2026-04-15 08:00 | 25.11 (-0.35%) | ||
| General meeting for 2026 | 2026-03-26 09:00 | 31.32 (+1.70%) | ||
| Annual report for 2025 | 2026-03-05 | 32.46 (+1.92%) |
Show
Entries
Flerie AB Frequently Asked Questions
What is Flerie AB(OSTO:FLERIE)'s stock price today?
The current price of OSTO:FLERIE is kr20.50. The 52 week high of OSTO:FLERIE is kr39.86 and 52 week low is kr19.40.
When is next earnings date of Flerie AB(OSTO:FLERIE)?
The next earnings date of Flerie AB(OSTO:FLERIE) is .
Does Flerie AB(OSTO:FLERIE) pay dividends? If so, how much?
Flerie AB(OSTO:FLERIE) does not pay dividend.
Press Release
Articles on Flerie AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers